1/4
About Polydex

As far back as 1969, we have been engaged in the manufacture of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry as well as the manufacture and marketing of biotechnology-based products for human pharmaceutical markets. Business is conducted through our wholly-owned subsidiaries, Dextran Products in Canada and Chemdex in the United States.

 

Common Shares

 

Shares Issued & Outstanding  -  3,432,978

An OTC Pink Foreign Issuer - POLXF

​Electronically Quoted with OTC Markets

Fiscal Year End  -  January 31st

Currently a SEC non-reporting issuer 

Recent News

 

May 2, 2022

Polydex Pharmaceuticals Issues Year End Financial Results

 

Management Pursuing New Opportunities and Markets for Product Line